检查点介导的三重信号人工抗原呈递细胞可有效促进抗原递送并激发全身性抗肿瘤免疫反应。
Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor immunity
Siyu Zhao, Tianzi Shi, Tianyi Tian, Fangming Zhang, Zitong Zhang, Hongbo Xu, Yixuan Zhou, Zhilang Li, Zhaojing Qin, Pengwen Xu, Conglian Yang, Zhiping Zhang
Journal:PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
IF:9.5
DOI:10.1073/pnas.2604171123
PMID:
Published:2026-08-05
research field:肿瘤学癌症代谢分子生物学药理学信号转导转录组学神经肿瘤学
Abstract
Dendritic cell (DC) vaccines offer professional antigen presentation but are often limited by suboptimal trafficking to lymphoid tissues, whereas whole tumor cell vaccines preserve antigenic diversity yet frequently lack coordinated activation cues for efficient T cell priming. Here, we report OncoAPC, an inactivated artificial antigen-presenting cell designed around a triple-signal priming logic: MHC-I-mediated antigen presentation (signal 1), CD80-mediated costimulation (signal 2) with checkpoint-insulating capacity, and incorporated IL-12 (signal 3). Mechanistically, OncoAPC directly activated T cells while partially insulating against PD-1 suppression through cis CD80:PD-L1 interactions and simultaneously engaged endogenous DCs to relay tumor antigens via cross-dressing and amplify lymphoid priming. Across multiple tumor models, OncoAPC showed broad therapeutic activity, including marked suppression of metastatic tumor burden and substantial control of established tumors, outperforming conventional DC vaccination. It further retained efficacy beyond the MC38 backbone and remained active when generated from human tumor cells or excised tumor-derived material. These findings establish OncoAPC as a scalable, broad-spectrum cancer vaccine platform that integrates antigenic diversity with DC-like functional precision.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


